Adjuvants induce distinct immunological phenotypes in a bovine tuberculosis vaccine model

Clinical and Vaccine Immunology

Volumn 16, Issue 10, 2009, Pages 1443-1448

  Vordermeier, H Martin ^a   Dean, Gillian S ^a   Rosenkrands, Ida ^b   Agger, Else M ^b   Andersen, Peter ^b   Kaveh, Daryan A ^a   Hewinson, R Glyn ^a   Hogarth, Philip J ^a  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CAF 01; DIMETHYLDIOCTADECYLBROMIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; ISA 206; ISA 50; ISA 70; LIPOSOME; MINERAL OIL; MYCOBACTERIUM ANTIGEN; PHOSPHATE BUFFERED SALINE; PROTEIN RV 3019 C; QUIL A; TREHALOSE 6,6' DIBEHENATE; UNCLASSIFIED DRUG; WATER OIL CREAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; BCG VACCINATION; CALF (BOVINE); CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; EFFECTOR CELL; EXPERIMENTAL MODEL; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BCG VACCINE; CATTLE; EMULSIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LIPOSOMES; MICE; MYCOBACTERIUM BOVIS; PHENOTYPE; SPECIES SPECIFICITY; T-LYMPHOCYTES; TUBERCULOSIS VACCINES; TUBERCULOSIS, BOVINE;

EID: 70349687746     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00229-09     Document Type: Article

References (32)

1. Agger, E. M., I. Rosenkrands, J. Hansen, K. Brahimi, B. S. Vandahl, C. Aagaard, K. Werninghaus, C. Kirschning, R. Lang, D. Christensen, M. Theisen, F. Follmann, and P. Andersen. 2008. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 3:e3116.
2. Andrews, N., R. Borrow, and E. Miller. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10:780-786.
3. Ashford, D. A., E. Whitney, P. Raghunathan, and O. Cosivi. 2001. Epidemiology of selected mycobacteria that infect humans and other animals. Rev. Sci. Tech. 20:325-337.
4. Bloom, B. R., and P. E. M. Fine. 1994. The BCG experience: implications for future vaccines against tuberculosis, p. 531-557. In B. H. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. ASM Press, Washington, DC.
5. Christensen, D., K. S. Korsholm, I. Rosenkrands, T. Lindenstrom, P. Andersen, and E. M. Agger. 2007. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 6:785-796.
6. Darrah, P. A., D. T. Patel, P. M. De Luca, R. W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, M. Roederer, and R. A. Seder. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13:843-850.
7. Davidsen, J., I. Rosenkrands, D. Christensen, A. Vangala, D. Kirby, Y. Perrie, E. M. Agger, and P. Andersen. 2005. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochim. Biophys. Acta 1718:22-31.
8. Gavin, A. L., K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, and D. Nemazee. 2006. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314:1936-1938.
9. Hogarth, P. J., R. G. Hewinson, and H. M. Vordermeier. 2006. Development of vaccines against bovine tuberculosis. J. Pharm. Pharmacol. 58:749-757.
10. Hogarth, P. J., K. E. Logan, H. M. Vordermeier, M. Singh, R. G. Hewinson, and M. A. Chambers. 2005. Protective immunity against Mycobacterium bovis induced by vaccination with Rv3019c - a member of the esat-6 gene family. Vaccine 23:2557-2564.
11. Holten-Andersen, L., T. M. Doherty, K. S. Korsholm, and P. Andersen. 2004. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect. Immun. 72:1608-1617.
12. Kaufmann, S. H. 2006. Envisioning future strategies for vaccination against tuberculosis. Nat. Rev. Immunol. 6:699-704.
13. Keating, S. M., P. Bejon, T. Berthoud, J. M. Vuola, S. Todryk, D. P. Webster, S. J. Dunachie, V. S. Moorthy, S. J. McConkey, S. C. Gilbert, and A. V. Hill. 2005. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175:5675-5680.
14. Korsholm, K. S., E. M. Agger, C. Foged, D. Christensen, J. Dietrich, C. S. Andersen, C. Geisler, and P. Andersen. 2007. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121:216-226.
15. Langermans, J. A., T. M. Doherty, R. A. Vervenne, T. van der Laan, K. Lyashchenko, R. Greenwald, E. M. Agger, C. Aagaard, H. Weiler, D. van Soolingen, W. Dalemans, A. W. Thomas, and P. Andersen. 2005. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23:2740-2750.
16. Lindenstrom, T., E. M. Agger, K. S. Korsholm, P. A. Darrah, C. Aagaard, R. A. Seder, I. Rosenkrands, and P. Andersen. 2009. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 182:8047-8055.
17. Ly, L. H., and D. N. McMurray. 2008. Tuberculosis: vaccines in the pipeline. Expert Rev. Vaccines 7:635-650.
18. Mittrucker, H. W., U. Steinhoff, A. Kohler, M. Krause, D. Lazar, P. Mex, D. Miekley, and S. H. Kaufmann. 2007. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc. Natl. Acad. Sci. USA 104:12434-12439.
19. O'Hagan, D. T., and R. Rappuoli. 2004. Novel approaches to vaccine delivery. Pharm. Res. 21:1519-1530.
20. Olsen, A. W., A. Williams, L. M. Okkels, G. Hatch, and P. Andersen. 2004. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72:6148-6150.
21. Orme, I. M. 2006. Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 24:2-19.
22. Reece, W. H., M. Pinder, P. K. Gothard, P. Milligan, K. Bojang, T. Doherty, M. Plebanski, P. Akinwunmi, S. Everaere, K. R. Watkins, G. Voss, N. Tornieporth, A. Alloueche, B. M. Greenwood, K. E. Kester, K. P. McAdam, J. Cohen, and A. V. Hill. 2004. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 10:406-410.
23. Rosenkrands, I., E. M. Agger, A. W. Olsen, K. S. Korsholm, C. S. Andersen, K. T. Jensen, and P. Andersen. 2005. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect. Immun. 73:5817-5826.
24. Su, S. B., P. B. Silver, R. S. Grajewski, R. K. Agarwal, J. Tang, C. C. Chan, and R. R. Caspi. 2005. Essential role of the MyD88 pathway, but non-essential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J. Immunol. 175:6303-6310.
25. Vordermeier, H. M., B. Villarreal-Ramos, P. J. Cockle, M. McAulay, S. G. Rhodes, T. Thacker, S. C. Gilbert, H. McShane, A. V. S. Hill, Z. Xing, and R. G. Hewinson. 2009. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect. Immun. 77:3364-3373.
26. Vordermeier, H. M., M. A. Chambers, P. J. Cockle, A. O. Whelan, J. Simmons, and R. G. Hewinson. 2002. Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect. Immun. 70:3026-3032.
27. Vordermeier, H. M., K. Huygen, M. Singh, R. G. Hewinson, and Z. Xing. 2006. Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing mycobacterial antigen 85A and Mycobacterium bovis BCG. Infect. Immun. 74:1416-1418.
28. Vordermeier, H. M., R. Pontarollo, B. Karvonen, P. Cockle, R. Hecker, M. Singh, L. A. Babiuk, R. G. Hewinson, and S. van Drunen Littel-van Den Hurk. 2005. Synthetic peptide vaccination in cattle: induction of strong cellular immune responses against peptides derived from the Mycobacterium bovis antigen Rv3019c. Vaccine 23:4375-4384.
29. Wang, J., and Z. Xing. 2002. Tuberculosis vaccines: the past, present and future. Expert Rev. Vaccines 1:341-354. (Pubitemid 36559869)
30. Waters, W. R., M. V. Palmer, B. J. Nonnecke, T. C. Thacker, C. F. Scherer, D. M. Estes, R. G. Hewinson, H. M. Vordermeier, S. W. Barnes, G. C. Federe, J. R. Walker, R. J. Glynne, T. Hsu, B. Weinrick, K. Biermann, M. H. Larsen, and W. R. Jacobs, Jr. 2009. Efficacy and immunogenicity of Mycobacterium bovis DeltaRD1 against aerosol M. bovis infection in neonatal calves. Vaccine 27:1201-1209.
31. Werninghaus, K., A. Babiak, O. Gross, C. Holscher, H. Dietrich, E. M. Agger, J. Mages, A. Mocsai, H. Schoenen, K. Finger, F. Nimmerjahn, G. D. Brown, C. Kirschning, A. Heit, P. Andersen, H. Wagner, J. Ruland, and R. Lang. 2009. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRγ-Syk-Card9-dependent innate immune activation. J. Exp. Med. 206:89-97.
32. Whelan, A. O., D. C. Wright, M. A. Chambers, M. Singh, R. G. Hewinson, and H. M. Vordermeier. 2008. Evidence for enhanced central memory priming by live Mycobacterium bovis BCG vaccine in comparison with killed BCG formulations. Vaccine 26:166-173.